Tech
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation – BMC Infectious Diseases
Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;18(11):1015–27. https://doi.org/10.1056/NEJMoa2031893.
Franchini M, Corsini F, Focosi D, Cruciani M. Safety and Efficacy of Convalescent plasma in COVID-19: an overview of systematic reviews. Diagnostics (Basel). 2021;11(9). https://doi.org/10.3390/diagnostics11091663.
Kimber C, Lamikanra AA, Geneen LJ, et al. A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza. Transfus Med. 2023;33(1):26–38. https://doi.org/10.1111/tme.12942.
Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):115–26. https://doi.org/10.1001/jamainternmed.2021.6850.
RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;29(10289):2049–59. https://doi.org/10.1016/s0140-6736(21)00897-7.
Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;18(7):619–29. https://doi.org/10.1056/NEJMoa2031304.
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;22:m3939. https://doi.org/10.1136/bmj.m3939.
O’Donnell MR, Grinsztejn B, Cummings MJ, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest. 2021;1(13). https://doi.org/10.1172/jci150646.
Bar KJ, Shaw PA, Choi GH, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;15(24). https://doi.org/10.1172/jci155114.
Belov A, Huang Y, Villa CH, et al. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol. 2022;97(6):770–9. https://doi.org/10.1002/ajh.26531.
Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;18(7):610–8. https://doi.org/10.1056/NEJMoa2033700.
Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022;386(18):1700–11. https://doi.org/10.1056/NEJMoa2119657.
Levine AC, Fukuta Y, Huaman MA, et al. Coronavirus disease 2019 Convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from 5 randomized trials. Clin Infect Dis. 2023;16(12):2077–86. https://doi.org/10.1093/cid/ciad088.
Focosi D, Franchini M, Pirofski LA, et al. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin Microbiol Rev. 2022;21(3):e0020021. https://doi.org/10.1128/cmr.00200-21.
Rojas M, Rodríguez Y, Hernández JC, et al. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. BMC Infect Dis. 2022;27(1):575. https://doi.org/10.1186/s12879-022-07560-7.
Misset B, Piagnerelli M, Hoste E, et al. Convalescent plasma for Covid-19-Induced ARDS in mechanically ventilated patients. N Engl J Med. 2023;26(17):1590–600. https://doi.org/10.1056/NEJMoa2209502.
Casadevall A, Pirofski LA. Misinterpretation of clinical research findings and COVID-19 mortality. Ann Intern Med. 2023;176(7):993–4. https://doi.org/10.7326/m23-0737.
Troxel AB, Petkova E, Goldfeld K, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a Meta-analysis. JAMA Netw Open. 2022;4(1):e2147331. https://doi.org/10.1001/jamanetworkopen.2021.47331.
Goldfeld KS, Wu D, Tarpey T, et al. Prospective individual patient data meta-analysis: evaluating convalescent plasma for COVID-19. Stat Med. 2021;30(24):5131–51. https://doi.org/10.1002/sim.9115.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-197. https://doi.org/10.1016/s1473-3099(20)30483-7.
Park H, Tarpey T, Liu M, et al. Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma. JAMA Netw Open. 2022;4(1):e2147375. https://doi.org/10.1001/jamanetworkopen.2021.47375.
Jorda A, Kussmann M, Kolenchery N, et al. Convalescent plasma treatment in patients with Covid-19: a systematic review and Meta-analysis. Front Immunol. 2022;13:817829. https://doi.org/10.3389/fimmu.2022.817829
Salazar E, Christensen PA, Graviss EA, et al. Significantly decreased mortality in a large cohort of Coronavirus Disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG. Am J Pathol. 2021;191(1):90–107. https://doi.org/10.1016/j.ajpath.2020.10.008.
Casadevall A, Pirofski LA, Joyner MJ. The principles of antibody therapy for infectious diseases with relevance for COVID-19. mBio. 2021;12(2):e03372-20. https://doi.org/10.1128/mBio.03372-20.
Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;17(8):599–609. https://doi.org/10.7326/0003-4819-145-8-200610170-00139.
Stadler E, Chai KL, Schlub TE, et al. Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis. Lancet Microbe. 2023;4(11):e883-892. https://doi.org/10.1016/s2666-5247(23)00194-5.
Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2023;3(1):e2250647. https://doi.org/10.1001/jamanetworkopen.2022.50647.
Herman JD, Wang C, Loos C, et al. Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. Nat Commun. 2021;25(1):6853. https://doi.org/10.1038/s41467-021-27201-y.
Herman JD, Wang C, Burke JS, et al. Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy. Cell Rep Med. 2022;15(11):100811. https://doi.org/10.1016/j.xcrm.2022.100811.
Salazar E, Kuchipudi SV, Christensen PA, et al. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest. 2020;1(12):6728–38. https://doi.org/10.1172/jci141206.
Askenase PW. COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: do the exosomes in convalescent plasma antagonize the weak immune antibodies? J Extracell Vesicles. 2020;10(1):e12004. https://doi.org/10.1002/jev2.12004.
Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol. 2003;170(7):3621–30. https://doi.org/10.4049/jimmunol.170.7.3621.
Goodner K, Horsfall FL. The protective action of type I antipneumococcus serum in mice: IV. The prozone. J Exp Med. 1936;31(3):369–75. https://doi.org/10.1084/jem.64.3.369.
Senefeld JW, Casadevall A, Joyner MJ. Convalescent plasma to deliver therapeutic antibodies against COVID-19. Trends Mol Med. 2022;28(5):435–6. https://doi.org/10.1016/j.molmed.2022.02.005.
Moog R. COVID 19 convalescent plasma: Is there still a place for CCP? Transfus Apher Sci. 2023;62(2):103680. https://doi.org/10.1016/j.transci.2023.103680.
Farnsworth CW, Case JB, Hock K, et al. Assessment of serological assays for identifying high titer convalescent plasma. Transfusion. 2021;61(9):2658–67. https://doi.org/10.1111/trf.16580.
Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61(3):275–91. https://doi.org/10.1016/s0009-9236(97)90160-0.
From Stadium to Screen: How Technology is Changing Sports Viewing
20/7/2024 Horse Racing Tips and Best Bets – Flemington, Flemington Cup day
Indian tech hub Karnataka state’s move to reserve jobs for locals not finalised, chief minister says
Financial picture dramatically improves for Shamrock Rovers in 48 hours with Sinclair Armstrong deal and European win
Our fashion editor’s favourite affordable bag is 20% off today
Jay Shah’s Big Decision Hovers Over Cricket’s Associate Member Directors Election
Budget shampoo that adds MAJOR volume boost is on sale for Amazon Prime Day: ‘Your hair feels fuller and thicker’
Being active on your commute lowers risk of disease and mental health
Tiger Woods cops brutal Open schedule as full Round 1 tee times revealed
